Response to: 'Patients with lupus with COVID-19: University of Michigan experience' by Wallace et al

Alexis Mathian¹, Zahir Amoura²

Affiliations

¹ Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupement Hospitalier Pitié-Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de Médecine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France alexis.mathian@aphp.fr.
² Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupement Hospitalier Pitié-Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de Médecine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France.

PMID: 32475832
DOI: 10.1136/annrheumdis-2020-217910

Comment

Response to: 'Patients with lupus with COVID-19: University of Michigan experience' by Wallace et al

Alexis Mathian et al. Ann Rheum Dis. 2021 Mar.

. 2021 Mar;80(3):e36.

doi: 10.1136/annrheumdis-2020-217910. Epub 2020 May 31.

Authors

Alexis Mathian¹, Zahir Amoura²

Affiliations

¹ Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupement Hospitalier Pitié-Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de Médecine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France alexis.mathian@aphp.fr.
² Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupement Hospitalier Pitié-Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de Médecine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France.

PMID: 32475832
DOI: 10.1136/annrheumdis-2020-217910

No abstract available

Keywords: hydroxychloroquine; lupus erythematosus, systemic; therapeutics.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Comment on

Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine.
Mathian A, Mahevas M, Rohmer J, Roumier M, Cohen-Aubart F, Amador-Borrero B, Barrelet A, Chauvet C, Chazal T, Delahousse M, Devaux M, Euvrard R, Fadlallah J, Florens N, Haroche J, Hié M, Juillard L, Lhote R, Maillet T, Richard-Colmant G, Palluy JB, Pha M, Perard L, Remy P, Rivière E, Sène D, Sève P, Morélot-Panzini C, Viallard JF, Virot JS, Benameur N, Zahr N, Yssel H, Godeau B, Amoura Z. Mathian A, et al. Ann Rheum Dis. 2020 Jun;79(6):837-839. doi: 10.1136/annrheumdis-2020-217566. Epub 2020 Apr 24. Ann Rheum Dis. 2020. PMID: 32332072 No abstract available.
Patients with lupus with COVID-19: University of Michigan experience.
Wallace B, Washer L, Marder W, Kahlenberg JM. Wallace B, et al. Ann Rheum Dis. 2021 Mar;80(3):e35. doi: 10.1136/annrheumdis-2020-217794. Epub 2020 May 31. Ann Rheum Dis. 2021. PMID: 32475835 Free PMC article. No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Response to: 'Patients with lupus with COVID-19: University of Michigan experience' by Wallace et al

Affiliations

Response to: 'Patients with lupus with COVID-19: University of Michigan experience' by Wallace et al

Authors

Affiliations

Conflict of interest statement

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical